Conference Program

Tuesday, November 3

1:00 p.m.-3:00 p.m.  Plenary Session 1: Genomics
Imperial Ballroom AB
Session Chairperson: Jonathan A. Fletcher, Brigham and Women’s Hospital, Boston, MA

1:00 p.m.  Identifying druggable mutations in pediatric solid tumors
Michael A. Dyer, St. Jude Children’s Research Hospital, Memphis, TN

1:20 p.m.  Novel monogenic and polygenic determinants of sarcoma risk: A clinic-based study of 1,162 families
David M. Thomas, Garvan Institute of Medical Research, Darlinghurst, Australia

1:40 p.m.  Sarcoma genomics: Discovery and application
Elaine Mardis, Washington University, St. Louis, MO

2:00 p.m.  Sarcoma functional genomics by human somatic cell mutagenesis
Rama Khokha, Princess Margaret Cancer Centre, Toronto, ON, Canada

2:20 p.m.  Open discussion

3:00 p.m.-3:30 p.m.  Break
Imperial Ballroom Foyer

3:30 p.m.-5:00 p.m.  Plenary Session 2: Metabolism
Imperial Ballroom AB
Session Chairperson: Robert G. Maki, Mount Sinai Medical Center, New York, NY

3:30 p.m.  Role of metabolism in cancer progression
Matthew G. Vander Heiden, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA

3:50 p.m.  Synovial sarcoma metabolomics landscape
Brian A. Van Tine, Washington University, St. Louis, MO

4:10 p.m.  Genetic and epigenetic classification of SDH-deficient gastrointestinal stromal tumor
Paul S. Meltzer, National Cancer Institute, Bethesda, MD

4:30 p.m.  Open discussion

5:00 p.m.-7:00 p.m.  Opening Reception
Imperial Ballroom CD
Wednesday, November 4

7:00 a.m.-8:00 a.m.  Continental Breakfast
Imperial Ballroom CD

8:00 a.m.-10:00 a.m.  Plenary Session 3: Epigenetics and Transcription
Imperial Ballroom AB
Session Chairperson: Brian A. Van Tine, Washington University, St. Louis, MO

8:00 a.m.  Reversing misdirected chromatin remodeling in synovial sarcoma
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, MA

8:20 a.m.  Identifying epigenetic vulnerabilities in MPNST
Karen Cichowski, Brigham and Women's Hospital, Boston, MA

8:40 a.m.  LSD Inhibitors in Ewing sarcoma
Stephen L. Lessnick, The Research Institute at Nationwide Children's Hospital, Columbus, OH

9:00 a.m.  Zebrafish xenograft validation of combination EWS-FLI1 and MDM2/TP53 targeting
Pancras Hogendoorn, Leiden University Medical Centre, Leiden, The Netherlands

9:20 a.m.  Open discussion

10:00 a.m.-10:30 a.m.  Break
Imperial Ballroom Foyer

10:30 a.m.-12:00 p.m.  Plenary Session 4: Immunology
Imperial Ballroom AB
Session Chairperson: Angelo Paolo Dei Tos, General Hospital of Treviso, Treviso, Italy

10:30 a.m.  A brief history of sarcoma immunotherapy
Robert G. Maki, Mount Sinai Medical Center, New York, NY

10:50 a.m.  Close interactions between dendritic cells and cancer
A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, Farmington, CT

11:10 a.m.  Overcoming the sarcoma microenvironment for effective immunotherapy
Seth Pollack, University of Washington School of Medicine, Seattle, WA

11:30 a.m.  Open discussion

12:00 p.m.-2:00 p.m.  Lunch on Own
2:00 p.m.-3:30 p.m.  **Plenary Session 5: Novel Mechanisms: Myogenic Tumors**  
Imperial Ballroom AB  
*Session Chairperson: Lee J. Helman, National Cancer Institute, Bethesda, MD*

2:00 p.m.  **Notch signaling increases the number of relapse-driving tumor propagating cells in embryonal rhabdomyosarcoma**  
David M. Langenau, Massachusetts General Hospital/Harvard Medical School, Boston, MA

2:20 p.m.  **Dynamic cell-cycle dependent regulation of PAX3-FOXO1 tumorigenic function**  
Charles Keller, Oregon Health Science University, Portland, OR

2:40 p.m.  **Speaker to be announced**

3:00 p.m. **Open discussion**

3:30 p.m. **Closing Remarks**

5:00 p.m.- **Start of CTOS Annual Meeting**